Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $58.00

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given a consensus rating of “Reduce” by the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $35.60.

A number of brokerages have commented on STRO. Wall Street Zen cut Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Wedbush reaffirmed a “neutral” rating and issued a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sutro Biopharma in a research report on Monday, December 1st.

Insider Activity

In other Sutro Biopharma news, Director Connie Matsui bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were bought at an average cost of $8.00 per share, with a total value of $40,000.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $40,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders bought 11,175 shares of company stock valued at $89,598 over the last quarter. 3.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sutro Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd bought a new stake in shares of Sutro Biopharma in the 2nd quarter worth approximately $27,000. Savant Capital LLC purchased a new stake in Sutro Biopharma in the second quarter worth $37,000. Bridgeway Capital Management LLC boosted its holdings in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares in the last quarter. CWM LLC boosted its holdings in Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after acquiring an additional 23,941 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in Sutro Biopharma by 174.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after purchasing an additional 38,561 shares during the period. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Up 6.0%

Sutro Biopharma stock opened at $9.00 on Monday. The firm has a fifty day simple moving average of $9.25 and a two-hundred day simple moving average of $8.74. Sutro Biopharma has a twelve month low of $5.23 and a twelve month high of $24.80. The company has a market capitalization of $76.59 million, a PE ratio of -0.34 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.25). The company had revenue of $9.69 million during the quarter, compared to analysts’ expectations of $10.14 million. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%. As a group, equities analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.